secwatch.observer — SEC 8-K summary
======================================

Issuer:     KalVista Pharmaceuticals, Inc. (KALV)
CIK:        0001348911
Form:       8-K
Filed at:   2024-07-11T23:59:59+00:00
Accession:  0000950170-24-082997
Event type: earnings
Sentiment:  neutral
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

KalVista submits NDA for sebetralstat; FY2024 net loss $126.6M
--------------------------------------------------------------

- NDA submitted to FDA for sebetralstat, first oral on-demand HAE treatment; potential approval H1 2025.
- FY2024 net loss $126.6M ($3.44/share) vs $92.9M ($3.33) prior year; no revenue.
- Cash, cash equivalents and marketable securities $210.4M, up from $149.4M; raised $150.1M net in Feb 2024 offering.
- R&D expenses $86.2M (prior $80.3M); G&A $54.3M (prior $30.6M) driven by commercial planning and employee costs.
- Promoted Benjamin Palleiko to CEO in March 2024; strategic review of preclinical Factor XIIa program ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024082997/0000950170-24-082997-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1348911/000095017024082997/kalv-20240711.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-082997

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer